[HTML][HTML] Translational genomics of nasopharyngeal cancer

CM Tsang, VWY Lui, JP Bruce, TJ Pugh… - Seminars in cancer biology, 2020 - Elsevier
Nasopharyngeal carcinoma (NPC), also named the Cantonese cancer, is a unique cancer
with strong etiological association with infection of the Epstein-Barr virus (EBV). With …

[PDF][PDF] Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy

SK Rehman, J Haynes, E Collignon, KR Brown… - Cell, 2021 - cell.com
Cancer cells enter a reversible drug-tolerant persister (DTP) state to evade death from
chemotherapy and targeted agents. It is increasingly appreciated that DTPs are important …

[HTML][HTML] Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab …

SY Cindy Yang, SC Lien, BX Wang… - Nature …, 2021 - nature.com
Serial circulating tumor DNA (ctDNA) monitoring is emerging as a non-invasive strategy to
predict and monitor immune checkpoint blockade (ICB) therapeutic efficacy across cancer …

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

S Lheureux, MC Cristea, JP Bruce, S Garg… - The Lancet, 2021 - thelancet.com
Summary Background The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have
shown preclinical synergy and promising activity in early phase clinical trials. We aimed to …

The genomic landscape of schwannoma

S Agnihotri, S Jalali, MR Wilson, A Danesh, M Li… - Nature …, 2016 - nature.com
Schwannomas are common peripheral nerve sheath tumors that can cause debilitating
morbidities. We performed an integrative analysis to determine genomic aberrations …

Human papillomavirus genotype association with survival in head and neck squamous cell carcinoma

SV Bratman, JP Bruce, B O'Sullivan, TJ Pugh… - JAMA …, 2016 - jamanetwork.com
Discussion| Our investigation shows that the use of Twitter for support (28%) and prevention
(28%) dialogues is common. Although some tweets are about clinical trials (18%), virtually …

EVOLVE: a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression

S Lheureux, A Oaknin, S Garg, JP Bruce… - Clinical Cancer …, 2020 - AACR
Purpose: PARP inhibitors (PARPi) are standard-of-care therapy for high-grade serous
ovarian cancer (HGSOC). We investigated combining cediranib (antiangiogenic) with …

[PDF][PDF] Patient-derived xenografts for prognostication and personalized treatment for head and neck squamous cell carcinoma

C Karamboulas, JP Bruce, AJ Hope, J Meens… - Cell reports, 2018 - cell.com
Overall survival remains very poor for patients diagnosed as having head and neck
squamous cell carcinoma (HNSCC). Identification of additional biomarkers and novel …

[HTML][HTML] Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study

M Oliva, D Chepeha, DV Araujo… - … for Immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Sitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and
the VEGF receptor family, is predicted to increase the M1 to M2-polarized tumor-associated …

[HTML][HTML] A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene

CT Fierheller, L Guitton-Sert, WM Alenezi, T Revil… - Genome medicine, 2021 - Springer
Familial ovarian cancer (OC) cases not harbouring pathogenic variants in either of the
BRCA1 and BRCA2 OC-predisposing genes, which function in homologous recombination …